지에프씨생명과학
Financials
Valuation Metrics
지에프씨생명과학's Market Cap is ₩309B. At end of 2025 it was ₩756B. Ranked #2064 of 2,421 in KR market (top 85%), #1320 of 1,640 on KOSDAQ (top 80%), #63 of 68 in Financial Services (top 93%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 30.94B KRW | KR#2,064/2,421 Sec#63/68 |
| Revenue | 17.71B KRW | KR#2,175/2,421 Sec#56/68 |
| Net Income | 555.4M KRW | KR#1,517/2,421 Sec#57/68 |
| Total Assets | 33.83B KRW | KR#2,313/2,421 Sec#61/68 |
| Net Assets | 23.80B KRW | KR#2,245/2,421 Sec#61/68 |
| Employees | 80 | KR#1,810/2,421 Sec#39/68 |
| Value | ||
| P/E | 55.71x | KR#1,430/2,421 Sec#57/68 |
| P/B | 1.30x | KR#1,681/2,421 Sec#49/68 |
| P/S | 1.75x | KR#1,724/2,421 Sec#41/68 |
| EV/EBITDA | 78.84x | KR#1,448/2,421 Sec#54/68 |
| FCF Yield | -20.51% | KR—/2,421 Sec—/68 |
| Profitability | ||
| ROE | 2.33% | KR#1,377/2,421 Sec#55/68 |
| ROA | 1.64% | KR#1,280/2,421 Sec#36/68 |
| Op. Margin | 2.18% | KR#1,358/2,421 Sec#55/68 |
| Revenue Growth | 5.42% | KR#1,173/2,421 Sec#42/68 |
| Financial Health | ||
| Debt Ratio | 42.16% | KR#837/2,421 Sec#20/68 |
| Total Debt | 6.98B KRW | KR#1,728/2,421 Sec#42/68 |
| FCF | -6.34B KRW | KR#1,566/2,421 Sec#31/68 |
| Cash | 7.47B KRW | KR#1,847/2,421 Sec#54/68 |
| Current Ratio | 5.60x | KR#245/2,421 Sec#3/68 |
| Net Debt/EBITDA | -1.26x | KR#326/2,421 Sec#14/68 |
| Performance | ||
| 1Y Return | -69.42% | KR#2,294/2,421 Sec#65/68 |
| 1M Return | 8.19% | KR#561/2,421 Sec#13/68 |
| From 52W High | -74.06% | KR#2,273/2,421 Sec#63/68 |
| 1Y MDD | -79.04% | KR#2,280/2,421 Sec#63/68 |
| Trading | ||
| Volume | 7,148 shares | KR#2,034/2,421 Sec#61/68 |
| Trading Value | 41.1M KRW | KR#1,905/2,421 Sec#58/68 |
| Foreign Own. | 2.91% | KR#1,317/2,421 Sec#36/68 |
| Per Share | ||
| EPS | 104 KRW | KR#1,415/2,421 Sec#55/68 |
| BPS | 4,469 KRW | KR#1,572/2,421 Sec#47/68 |
Company Info
GFC Life Science, established in 2002, listed on KONEX in 2022 and transferred to KOSDAQ in 2025. The company specializes in developing and producing cosmetic biomaterials using skin microbiome and exosome technologies, alongside providing efficacy testing and advertising substantiation data for functional cosmetics. Leveraging a library of over 2,000 strains, more than 80 patented microorganisms, and patented exosome isolation and purification technology, it is actively developing skin booster products and pursuing global market expansion. GFC Life Science is headquartered in Hwaseong-si, Gyeonggi-do.